Ulland Investment Advisors LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 200 shares of the company’s stock after selling 14 shares during the period. Ulland Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $177,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Scarborough Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 7.4% during the fourth quarter. Scarborough Advisors LLC now owns 465 shares of the company’s stock valued at $271,000 after purchasing an additional 32 shares during the last quarter. Richardson Financial Services Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $43,000. Warren Street Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 15.4% during the fourth quarter. Warren Street Wealth Advisors LLC now owns 964 shares of the company’s stock valued at $562,000 after purchasing an additional 129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Eli Lilly and Company by 38.6% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 417,700 shares of the company’s stock valued at $243,486,000 after purchasing an additional 116,300 shares during the period. Finally, Livelsberger Financial Advisory purchased a new stake in Eli Lilly and Company in the fourth quarter worth approximately $135,000. Institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Citigroup initiated coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective for the company. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $979.29.
Eli Lilly and Company Price Performance
Shares of LLY traded down $16.58 during midday trading on Tuesday, hitting $912.93. 928,126 shares of the company traded hands, compared to its average volume of 2,991,765. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a 50 day moving average of $913.95 and a 200-day moving average of $854.46. The stock has a market cap of $867.65 billion, a price-to-earnings ratio of 134.19, a PEG ratio of 2.79 and a beta of 0.42.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Manufacturing Stocks Investing
- AMD Gains Momentum With AI: Can It Beat Expectations?
- 3 Best Fintech Stocks for a Portfolio Boost
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Seize the Opportunity: 2 High-Yield Stocks for Your Portfolio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.